Mehdi Gasmi

Chief Operating Officer at SparingVision

Mehdi Gasmi has a diverse work experience spanning over several companies and roles. In 1997, they began their career as a Postdoctoral Scientist at Viagene/Chiron Corporation, followed by positions as Scientist II at Cell Genesys and Chiron Corporation. In 2000, they worked as a Scientist at uc.

From 2001 to 2009, Gasmi served as the Sr. Director of Product Development at Ceregene, Inc. Mehdi then joined Genethon in 2009 as the VP of Product Development & Manufacturing. In 2011, they became a Principal at ClinVec Solutions, LLC and held the role until 2013.

Gasmi's extensive tenure at Adverum Biotechnologies, Inc. began in 2013 when they became the Chief Science and Technology Officer and SVP of Pharmaceutical Development. Mehdi went on to serve as the President and Chief Scientific Officer from 2018 to 2019. Additionally, they were a Board Member during their time at the company.

Currently, Gasmi serves as the Chief Operating Officer at SparingVision, a position they started in November 2021.

Mehdi Gasmi completed their education at Université Claude Bernard Lyon 1, where they pursued a Ph.D. in Biochemistry from 1984 to 1996.

Location

Paris, France

Links


Org chart


Teams

This person is not in any teams


Offices


SparingVision

SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent drug candidate to treat retinitis pigmentosa, the most common inherited retinal degeneration.


Industries

Headquarters

Paris, France

Employees

11-50

Links